Literature DB >> 21656322

[Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology].

C Warnke, O Adams, H P Hartung, R Gold, B Hemmer, R Hohlfeld, M Stangel, F Zipp, H Wiendl, B C Kieseier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21656322     DOI： 10.1007/s00115-011-3319-2

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


× No keyword cloud information.
  18 in total

Review 1.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

2.  Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.

Authors:  Richard A Rudick; Paul W O'Connor; Chris H Polman; Andrew D Goodman; Soma S Ray; Nancy M Griffith; Stephanie A Jurgensen; Leonid Gorelik; Fiona Forrestal; Alfred W Sandrock; Susan E Goelz
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

Review 3.  Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.

Authors:  M Mehling; T A Johnson; J Antel; L Kappos; A Bar-Or
Journal:  Neurology       Date:  2011-02-22       Impact factor: 9.910

Review 4.  Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

Authors:  Clemens Warnke; Til Menge; Hans-Peter Hartung; Michael K Racke; Petra D Cravens; Jeffrey L Bennett; Elliot M Frohman; Benjamin M Greenberg; Scott S Zamvil; Ralf Gold; Bernhard Hemmer; Bernd C Kieseier; Olaf Stüve
Journal:  Arch Neurol       Date:  2010-08

5.  Characterization of JC human polyomavirus infection in a Portuguese population.

Authors:  Ana Matos; Vitor Duque; Sílvia Beato; João Poiares da Silva; Eugene Major; António Meliço-Silvestre
Journal:  J Med Virol       Date:  2010-03       Impact factor: 2.327

6.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

7.  Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40.

Authors:  Wendy A Knowles; Pam Pipkin; Nick Andrews; Andrew Vyse; Philip Minor; David W G Brown; Elizabeth Miller
Journal:  J Med Virol       Date:  2003-09       Impact factor: 2.327

8.  Seroepidemiology of the human polyomaviruses.

Authors:  Annika Stolt; Kestutis Sasnauskas; Pentti Koskela; Matti Lehtinen; Joakim Dillner
Journal:  J Gen Virol       Date:  2003-06       Impact factor: 3.891

9.  Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders.

Authors:  Aiden Haghikia; Moritz Perrech; Bartosz Pula; Sabrina Ruhrmann; Anja Potthoff; Norbert H Brockmeyer; Susan Goelz; Heinz Wiendl; Hans Lindå; Tjalf Ziemssen; Sergio E Baranzini; Tor-Björn Käll; Dietmar Bengel; Tomas Olsson; Ralf Gold; Andrew Chan
Journal:  PLoS One       Date:  2011-04-20       Impact factor: 3.240

10.  Seroepidemiology of human polyomaviruses.

Authors:  Jaime M Kean; Suchitra Rao; Michael Wang; Robert L Garcea
Journal:  PLoS Pathog       Date:  2009-03-27       Impact factor: 6.823
View more
  2 in total

Review 1.  [Teriflunomide for treatment of multiple sclerosis].

Authors:  C Warnke; G Meyer Zu Hörste; T Menge; O Stüve; H-P Hartung; H Wiendl; B C Kieseier
Journal:  Nervenarzt       Date:  2013-06       Impact factor: 1.214

2.  Changes to anti-JCV antibody levels in a Swedish national MS cohort.

Authors:  Clemens Warnke; Ryan Ramanujam; Tatiana Plavina; Tomas Bergström; Susan Goelz; Meena Subramanyam; Ingrid Kockum; Afsar Rahbar; Bernd C Kieseier; Carolina Holmén; Tomas Olsson; Jan Hillert; Anna Fogdell-Hahn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-03-05       Impact factor: 10.154
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.